Panel Discussion: Future Directions & Strategic Investment to Fuel the Next Wave of Neuropsychiatric Therapeutics

• How has investor sentiment evolved as neuropsychiatry moves from scientific validation toward commercial execution and scalability?
• What constitutes an attractive opportunity in today's investment landscape?
• How are investors evaluating next-generation psychedelic approaches, including non-hallucinogenic neuroplastogens and differentiated product profiles?
• Which emerging therapeutic areas and indications are generating the greatest excitement across neuropsychiatry?
• What scientific, clinical and commercial milestones are investors looking for before committing capital?

Speakers:

Natalie Sacks

Partner

Novo Holdings US

Chris Weyrer

Principal

Vida Ventures

Ritu Baral

Managing Director, Health Care – Biotechnology Research Analyst

Cowen

Aaron Koenig

Chief Medical Officer

Delix Therapeutics

Paul Matteis

Managing Director & Head of Therapeutics Research Stifel

Stifel

Jason Pitts

Principal

General Atlantic